Trigran Investments Inc. Has $51.27 Million Holdings in MiMedx Group, Inc $MDXG

Trigran Investments Inc. raised its position in MiMedx Group, Inc (NASDAQ:MDXG) by 10.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 8,390,458 shares of the company’s stock after buying an additional 790,901 shares during the period. MiMedx Group makes up 8.9% of Trigran Investments Inc.’s portfolio, making the stock its 4th biggest holding. Trigran Investments Inc. owned about 0.06% of MiMedx Group worth $51,266,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. CWM LLC lifted its holdings in shares of MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after purchasing an additional 1,892 shares during the period. Virtus Advisers LLC acquired a new stake in MiMedx Group in the first quarter valued at $40,000. PNC Financial Services Group Inc. raised its position in MiMedx Group by 1,808.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after purchasing an additional 7,107 shares during the last quarter. AQR Capital Management LLC lifted its holdings in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after buying an additional 4,296 shares during the period. Finally, Focus Partners Wealth bought a new stake in shares of MiMedx Group in the 1st quarter valued at about $128,000. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Stock Performance

Shares of MDXG opened at $6.86 on Friday. The stock has a 50 day moving average of $7.00 and a 200 day moving average of $6.83. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of 25.41 and a beta of 1.64. MiMedx Group, Inc has a 12 month low of $5.79 and a 12 month high of $10.14. The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Monday, November 13th. The company reported ($0.03) earnings per share for the quarter. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. The company had revenue of $67.69 million for the quarter. As a group, sell-side analysts forecast that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider owned 236,982 shares of the company’s stock, valued at $1,758,406.44. The trade was a 19.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.70% of the stock is owned by insiders.

Analysts Set New Price Targets

MDXG has been the topic of a number of recent analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of MiMedx Group in a research report on Tuesday, November 25th. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.